Skip to main content
SpringerLink
Log in

Antiviral therapy in the liver transplant candidate and recipient

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Antiviral therapy for patients with chronic hepatitis C who have cirrhosis, especially with decompensated disease, or have undergone liver transplantation, is evolving. Response to antiviral therapy declines with increasing severity of liver disease, genotype 1 infection, and dose reductions in antiviral therapy. Results in 79 patients indicate that 23% of post-transplant recurrence of hepatitis C may be prevented by pretransplant antiviral therapy. Rates of sustained virologic response with interferon or pegylated interferon plus ribavirin when used after transplantation range from 7% to 56%. Carefully controlled trials are needed to expand on these observations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. World Health Organization: Weekly Epidemiological Record. 1999, 74:421–428. Accessible online at http://www.who.int/docstore/wer/pdf/1999/wer7449.pdf

    Google Scholar 

  2. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS: The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000, 31:777–782. This paper defined the future for patient outcome and economic burden of liver disease due to chronic hepatitis C.

    Article  PubMed  CAS  Google Scholar 

  3. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999, 340:1228–1233.

    Article  PubMed  CAS  Google Scholar 

  4. Wiese M, Berr F, Lafrenz M, et al.: Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology. 2000, 32:91–96.

    Article  PubMed  CAS  Google Scholar 

  5. Seeff LB, Buskell-Bales Z, Wright EC, et al.: Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992, 327:1906–1911.

    Article  PubMed  CAS  Google Scholar 

  6. Seeff LB: Natural history of hepatitis C. Am J Med. 1999, 107:10S-15S.

    Article  PubMed  CAS  Google Scholar 

  7. Rodger AJ, Roberts S, Lanigan A, et al.: Assessment of longterm outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000, 32:582–587.

    Article  PubMed  CAS  Google Scholar 

  8. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995, 332:1463–1466.

    Article  PubMed  CAS  Google Scholar 

  9. Fattovich G, Giustina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997, 112:463–472.

    Article  PubMed  CAS  Google Scholar 

  10. Serfaty L, Aumaitre H, Chazouilleres O, et al.: Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998, 27:1435–1440.

    Article  PubMed  CAS  Google Scholar 

  11. Hu KQ, Tong MJ: The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999, 29:1311–1316.

    Article  PubMed  CAS  Google Scholar 

  12. Khan MH, Farrell GC, Byth K, et al.: Which patients with hepatitis C develop liver complications? Hepatology. 2000, 31:513–520.

    Article  PubMed  CAS  Google Scholar 

  13. Wiesner RH, Sorrell M, Villamil F: Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis C. Liver Transpl. 2003, 9(suppl 3):S1-S9.

    Article  PubMed  Google Scholar 

  14. Strader DB, Wright T, Thomas DL, Seeff LB: AASLD Practice Guidelines: Diagnosis, Management, and Treatment of Hepatitis C. Hepatology. 2004, 39:1147–1171.

    Article  PubMed  Google Scholar 

  15. Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C, with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989, 321:1501–1506.

    Article  PubMed  CAS  Google Scholar 

  16. Di Bisceglie AM, Martin P, Kassianides C, et al.: Recombinant Interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989, 321:1506–1510.

    Article  PubMed  Google Scholar 

  17. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med. 1997, 336:347–356.

    Article  PubMed  CAS  Google Scholar 

  18. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339:1485–1492.

    Article  PubMed  CAS  Google Scholar 

  19. Davis GL, Esteban-Mur R, Rustgi V, et al.: Interferon alfa-2b alone or in combination with Ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998, 339:1493–1499.

    Article  PubMed  CAS  Google Scholar 

  20. Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000, 343:1673–1680. Treatment was restricted to patients with either biopsy-proven cirrhosis (78%) or advanced fibrosis.

    Article  PubMed  CAS  Google Scholar 

  21. Fried MW, Shiffman ML, Reddy RK, et al.: Peginterferon alfa-2a plus Ribavirin for chronic hepatitis C Infection. N Engl J Med 2002, 347:975–982.

    Article  PubMed  CAS  Google Scholar 

  22. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. International Hepatitis Interventional Therapy Group. Lancet. 2001, 358:958–965.

    Article  PubMed  CAS  Google Scholar 

  23. Hadziyannis SJ, Sette H, Morgan TR, et al.: Peginterferon alfa-2a and Ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004, 140:346–355.

    PubMed  CAS  Google Scholar 

  24. Everson G, Heathcote J, Pappas SC, et al.: Histologic benefit of peginterferon alfa-2 (40KD) (PEGASYS) monotherapy in patients with advanced fibrosis or cirrhosis due to chronic hepatitis C. Hepatology. 2004, 40:316A.

    Google Scholar 

  25. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. HALT-C Trial Group. Gastroenterology. 2004, 126:1015–1023. Results of retreatment of prior nonresponders with fibrosis or cirrhosis using peginterferon alfa-2a plus ribavirin are discussed.

    Article  PubMed  CAS  Google Scholar 

  26. Everson GT, Hoefs JC, Malet P: Impaired virologic response in patients with advanced liver disease due to chronic hepatitis C is independently linked to severity of disease: results from the HALT C Trial. Hepatology. 2004, 40:180A.

    Google Scholar 

  27. Everson GT, Trotter JF, Kugelmas M: Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol [low-acceleratingdose-regimen]. Hepatology. 2002, 36:297A.

    Article  CAS  Google Scholar 

  28. Everson GT: Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl. 2003, 9(suppl 3):S90-S94. This is the initial discussion and experience in the treatment of patients with decompensated disease.

    Article  PubMed  Google Scholar 

  29. Dieterich DT, Wasserman R, Brau N, et al.: Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003, 98:2491–2499.

    PubMed  CAS  Google Scholar 

  30. Forns X, Garcia-Retortillo M, Serrano T, et al.: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003, 39:389–396. A prospective pilot study using interferon alfa-2b plus ribavirin in the month prior to transplantation.

    Article  PubMed  CAS  Google Scholar 

  31. Makiyama A, Itoh Y, Kasahara A, et al.: Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004, 101:1616–1622.

    Article  PubMed  CAS  Google Scholar 

  32. Shiffman ML, Hofmann CM, Thompson EB, et al.: Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997, 26:780–785.

    Article  PubMed  CAS  Google Scholar 

  33. Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002, 122:1303–1313.

    Article  PubMed  CAS  Google Scholar 

  34. Yoshida H, Shiratori Y, Moriyama M, et al.: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan: IHIT Study Group— Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999, 131:174–181.

    PubMed  CAS  Google Scholar 

  35. Shiffman ML, Hofmann CM, Contos MJ, et al.: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999, 117:1164–1172.

    Article  PubMed  CAS  Google Scholar 

  36. Alric L, Duffaut M, Selves J, et al.: Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol. 2001, 35:272–278.

    Article  PubMed  CAS  Google Scholar 

  37. Lee WM, Dienstag JL, Lindsay KL, et al.: Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004, 25:472–492.

    Article  PubMed  CAS  Google Scholar 

  38. Afdhal N, Levine R, Black M: Colchicine versus PEG-Intron long term: 1 year data from the COPILOT study [abstract]. Gastroenterology. 2002, 122:P-218.

    Google Scholar 

  39. Afdhal N, Freilich B, Levine R, et al.: Colchicine versus Peg-Intron Long-Term (COPILOT) Trial: interim analysis of clinical outcomes at year 2. Hepatology. 2004, 40:238A.

    Google Scholar 

  40. Thomas RM, Brems JJ, Guzman-Hartman G, et al.: Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003, 9:905–915. The authors described their experience with interferon monotherapy prior to transplantation.

    Article  PubMed  Google Scholar 

  41. Crippin JS, McCashland T, Terrault N, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002, 8:350–355. Results of a randomized controlled trial of low-dose antiviral therapy in decompensated patients.

    Article  PubMed  Google Scholar 

  42. Heathcote EJ: Treatment considerations in patients with hepatitis C and cirrhosis. J Clin Gastroenterol. 2003, 37:395–398.

    Article  PubMed  Google Scholar 

  43. Fontana RJ, Everson GT, Tuteja S, et al.: Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol. 2004, 2:183–197.

    Article  PubMed  Google Scholar 

  44. Berenguer M: Natural history of recurrent hepatitis C. Liver Transpl. 2002, 8:S14-S18.

    Article  PubMed  Google Scholar 

  45. Trotter JF, Talamantes M, McClure M, et al.: Right hepatic lobe donation for living donor liver transplantation: impact on donor quality of life. Liver Transpl. 2001, 7:485–493.

    Article  PubMed  CAS  Google Scholar 

  46. Trotter JF, Wachs M, Trouillot T, et al.: Evaluation of 100 patients for living donor liver transplantation. Liver Transpl 2000, 6:290–295.

    Article  PubMed  CAS  Google Scholar 

  47. Trotter J, Schiano T, Wachs M, et al.: Living donor liver transplantation in hepatitis C patients: short-term results compared to cadaveric transplantation. Am J Transpl. 2001, 1S:316A.

    Google Scholar 

  48. Garcia-Retortillo M, Forns X, Llovet JM, et al.: Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology. 2004, 40:699–707.

    Article  PubMed  Google Scholar 

  49. Sheiner PA, Boros P, Klion FM, et al.: The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998, 28:831–838.

    Article  PubMed  CAS  Google Scholar 

  50. Singh N, Gayowski T, Wannstedt CF, et al.: Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation. 1998, 65:82–86.

    Article  PubMed  CAS  Google Scholar 

  51. Mazzaferro V, Tagger A, Schiavo M, et al.: Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc. 2001, 33:1355–1357.

    Article  PubMed  CAS  Google Scholar 

  52. Feray C, Samuel D, Gigou M, et al.: An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology. 1995, 22(4 Pt 1):1084–1089.

    Article  PubMed  CAS  Google Scholar 

  53. Wright HI, Gavaler JS, Van Theil DH: Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation. 1992, 53:121–124.

    Article  PubMed  CAS  Google Scholar 

  54. Wright TL, Combs C, Kim M, et al.: Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology. 1994, 20(4 Pt 1):773–779.

    Article  PubMed  CAS  Google Scholar 

  55. Gane EJ, Lo SK, Riordan SM, et al.: A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998, 27:1403–1407.

    Article  PubMed  CAS  Google Scholar 

  56. Samuel D, Bizollon T, Feray C, et al.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003, 124:642–650. European study describing results using combination therapy after liver transplantation.

    Article  PubMed  CAS  Google Scholar 

  57. Gotz G, Schon MR, Haefker A, et al.: Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin. Transplant Proc. 1998, 30:2104–2106.

    Article  PubMed  CAS  Google Scholar 

  58. De Vera ME, Smallwood GA, Rosado K, et al.: Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation. 2001, 71:678–686.

    Article  PubMed  Google Scholar 

  59. Kornberg A, Hommann M, Tannapfel A, et al.: Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients. Am J Transplant 2001, 1:350–355.

    Article  PubMed  CAS  Google Scholar 

  60. Gopal DV, Rabkin JM, Berk BS, et al.: Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl. 2001, 7:181–190.

    Article  PubMed  CAS  Google Scholar 

  61. Alberti AB, Belli LS, Airoldi A, et al.: Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl. 2001, 7:870–876.

    Article  PubMed  CAS  Google Scholar 

  62. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al.: Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002, 8:623–629.

    Article  PubMed  Google Scholar 

  63. Ahmad J, Dodson SF, Demetris AJ, et al.: Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl. 2001, 7:863–869.

    Article  PubMed  CAS  Google Scholar 

  64. Shakil AO, McGuire B, Crippin J, et al.: A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. 2002, 36:1253–1258.

    Article  PubMed  CAS  Google Scholar 

  65. Samuel D, Bizollon T, Feray C, et al.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003, 124:642–650.

    Article  PubMed  CAS  Google Scholar 

  66. Lavezzo B, Franchello A, Smedile A, et al.: Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol. 2002, 37:247–252.

    Article  PubMed  CAS  Google Scholar 

  67. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al.: Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002, 8:1000–1006. Single-center U.S. experience in the treatment of liver recipients with combination therapy.

    Article  PubMed  Google Scholar 

  68. Giostra E, Kullak-Ublick GA, Keller W, et al.: Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int. 2004, 17:169–176.

    PubMed  CAS  Google Scholar 

  69. Mukherjee S, Gilroy RK, McCashland TM, Schafer DF: Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplant Proc. 2003, 35:1478–1479.

    Article  PubMed  CAS  Google Scholar 

  70. Rodriguez-Luna H, Khatib A, Sharma P, et al.: Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004, 77:190–194.

    Article  PubMed  CAS  Google Scholar 

  71. Neff GW, O’Brien CB, Cirocco R, et al.: Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl. 2004, 10:595–598. Measurement of tissue HCV RNA in allograft biopsies may predict SVR.

    Article  PubMed  Google Scholar 

  72. Ross AS, Bhan AK, Pascual M, et al.: Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant. 2004, 18:166–173.

    Article  PubMed  Google Scholar 

  73. Dumortier J, Scoazec JY, Chevallier P, Boillot O: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol. 2004, 40:669–674.

    Article  PubMed  CAS  Google Scholar 

  74. Quadri R, Giostra E, Roskams T, et al.: Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation. 2002, 73:373–378.

    Article  PubMed  CAS  Google Scholar 

  75. Cattral MS, Hemming AW, Wanless IR, et al.: Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation. 1999, 67:1277–1280.

    Article  PubMed  CAS  Google Scholar 

  76. Kugelmas M, Osgood MJ, Trotter JF, et al.: Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003, 9:1159–1165. Post-transplantation clearance of HCV RNA during interferon therapy may increase risk for allograft rejection.

    Article  PubMed  Google Scholar 

  77. Gopal DV, Rosen HR: Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl. 2003, 9:348–353.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B-154, 80262, Denver, CO, USA

    Gregory T. Everson MD

Authors
  1. Gregory T. Everson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Everson, G.T. Antiviral therapy in the liver transplant candidate and recipient. Curr hepatitis rep 4, 75–82 (2005). https://doi.org/10.1007/s11901-005-0018-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-005-0018-0

Keywords

Search

Navigation